These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25534390)

  • 21. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
    Warner E; Plewes DB; Hill KA; Causer PA; Zubovits JT; Jong RA; Cutrara MR; DeBoer G; Yaffe MJ; Messner SJ; Meschino WS; Piron CA; Narod SA
    JAMA; 2004 Sep; 292(11):1317-25. PubMed ID: 15367553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MRI and mammography surveillance of women at increased risk for breast cancer: recommendations using an evidence-based approach.
    Granader EJ; Dwamena B; Carlos RC
    Acad Radiol; 2008 Dec; 15(12):1590-5. PubMed ID: 19000876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis.
    Phi XA; Houssami N; Hooning MJ; Riedl CC; Leach MO; Sardanelli F; Warner E; Trop I; Saadatmand S; Tilanus-Linthorst MMA; Helbich TH; van den Heuvel ER; de Koning HJ; Obdeijn IM; de Bock GH
    Eur J Cancer; 2017 Nov; 85():31-38. PubMed ID: 28886475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study.
    Walsh EM; Farrell MP; Nolan C; Gallagher F; Clarke R; McCaffrey JA; Kennedy MJ; Barry M; Kell MR; Gallagher DJ
    Ir J Med Sci; 2016 Feb; 185(1):189-94. PubMed ID: 25673166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results.
    Sardanelli F; Podo F; D'Agnolo G; Verdecchia A; Santaquilani M; Musumeci R; Trecate G; Manoukian S; Morassut S; de Giacomi C; Federico M; Cortesi L; Corcione S; Cirillo S; Marra V; ; Cilotti A; Di Maggio C; Fausto A; Preda L; Zuiani C; Contegiacomo A; Orlacchio A; Calabrese M; Bonomo L; Di Cesare E; Tonutti M; Panizza P; Del Maschio A
    Radiology; 2007 Mar; 242(3):698-715. PubMed ID: 17244718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
    Obdeijn IM; Winter-Warnars GA; Mann RM; Hooning MJ; Hunink MG; Tilanus-Linthorst MM
    Breast Cancer Res Treat; 2014 Apr; 144(3):577-82. PubMed ID: 24567197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of clinical breast examination in a breast cancer surveillance program for women with germline BRCA1 or BRCA2 mutations.
    Hettipathirana T; Macdonald C; Xie J; Moodie K; Michael C; Phillips KA
    Med J Aust; 2021 Nov; 215(10):460-464. PubMed ID: 34420218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical breast exam contribution to breast cancer diagnosis in BRCA mutation carriers vs. average to intermediate risk women.
    Menes TS; Zippel D; Sklair-Levy M; Friedman E; Bernstein-Molho R; Faermann R; Madorsky Feldman D
    Breast Cancer Res Treat; 2024 Aug; 207(1):111-118. PubMed ID: 38797791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.
    Heijnsdijk EA; Warner E; Gilbert FJ; Tilanus-Linthorst MM; Evans G; Causer PA; Eeles RA; Kaas R; Draisma G; Ramsay EA; Warren RM; Hill KA; Hoogerbrugge N; Wasser MN; Bergers E; Oosterwijk JC; Hooning MJ; Rutgers EJ; Klijn JG; Plewes DB; Leach MO; de Koning HJ
    Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1458-68. PubMed ID: 22744338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Performance Measures of Magnetic Resonance Imaging Plus Mammography in the High Risk Ontario Breast Screening Program.
    Chiarelli AM; Blackmore KM; Muradali D; Done SJ; Majpruz V; Weerasinghe A; Mirea L; Eisen A; Rabeneck L; Warner E
    J Natl Cancer Inst; 2020 Feb; 112(2):136-144. PubMed ID: 31233143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
    Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
    J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing?
    Larouche G; Chiquette J; Pelletier S; Simard J; Dorval M
    Fam Cancer; 2017 Jan; 16(1):35-40. PubMed ID: 27554086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
    Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
    JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
    Pataky R; Armstrong L; Chia S; Coldman AJ; Kim-Sing C; McGillivray B; Scott J; Wilson CM; Peacock S
    BMC Cancer; 2013 Jul; 13():339. PubMed ID: 23837641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abnormal Findings Detected by Multi-modality Breast Imaging and Biopsy Results in a High-risk Clinic.
    Laitman Y; Feldman DM; Sklair-Levy M; Yosepovich A; Barshack-Nakar I; Brodsky M; Halshtok O; Shalmon A; Gotlieb M; Friedman E
    Clin Breast Cancer; 2018 Aug; 18(4):e695-e698. PubMed ID: 29292184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
    Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
    Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer.
    Le-Petross HT; Whitman GJ; Atchley DP; Yuan Y; Gutierrez-Barrera A; Hortobagyi GN; Litton JK; Arun BK
    Cancer; 2011 Sep; 117(17):3900-7. PubMed ID: 21365619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening of women at high risk for breast cancer.
    Narod SA
    Prev Med; 2011 Sep; 53(3):127-30. PubMed ID: 21745498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program.
    Chiarelli AM; Prummel MV; Muradali D; Majpruz V; Horgan M; Carroll JC; Eisen A; Meschino WS; Shumak RS; Warner E; Rabeneck L
    J Clin Oncol; 2014 Jul; 32(21):2224-30. PubMed ID: 24934793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Choices for women at risk of hereditary breast cancer].
    Saadatmand S; Obdeijn IM; Koppert LB; Tilanus-Linthorst M
    Ned Tijdschr Geneeskd; 2013; 157(43):A6625. PubMed ID: 24152366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.